Clinical Trials Logo

Filter by:
  • Available  
  • Page [1]
NCT ID: NCT05683548 Available - Clinical trials for Hepatocellular Carcinoma

Replicor Compassionate Access Program

RCAP
Start date: n/a
Phase:
Study type: Expanded Access

The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to response to other other antiviral agents either approved or under development and who are in danger of progressing to decompensated cirrhosis. This compassionate access program will provide access to a once weekly regimen of subcutaneously (SC) administered REP 2139-Mg for a period of 48 weeks with the goal of achieving functional cure of HDV and or HBV, with the reversal of liver disease in the absence of antiviral therapy. The safety, tolerability and efficacy of SC REP 2139-Mg will be monitored during and after therapy

NCT ID: NCT04564755 Available - Atopic Dermatitis Clinical Trials

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

Start date: n/a
Phase:
Study type: Expanded Access

This is a multi-center, expanded access protocol to provide access to the investigational product, abrocitinib, to adolescent and adult patients with moderate to severe atopic dermatitis who have inadequate treatment options with available and approved medicated topical and systemic therapies and who are otherwise ineligible for participation in clinical studies with abrocitinib.

NCT ID: NCT03994627 Available - Soft Tissue Sarcoma Clinical Trials

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).